Moderna Initiates Hantavirus Vaccine Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy MRNA?
Source: seekingalpha
- Vaccine Development Progress: Moderna is collaborating with the U.S. Army Medical Research Institute of Infectious Diseases to develop a hantavirus vaccine in early stages, although availability may take years, reflecting the company's commitment to addressing emerging infectious diseases.
- Positive Market Reaction: Moderna's shares rose approximately 14% in Friday afternoon trading, indicating investor optimism regarding the new vaccine development, which could enhance its market competitiveness.
- Epidemic Context Impact: Hantavirus has gained renewed attention due to an outbreak on the MV Hondius cruise ship, which resulted in three deaths and at least six infections, highlighting the urgency for vaccine development as noted by the World Health Organization.
- Funding Challenges and Outlook: Despite the challenges of insufficient funding for hantavirus vaccine development, experts suggest that without significant government investment, the timeline for vaccine availability could extend to a decade or more, impacting the company's long-term strategic planning.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 54.350
Low
17.00
Averages
32.47
High
63.00
Current: 54.350
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is engaged in developing medicines across infectious disease vaccines, oncology therapeutics and rare disease therapeutics. Its platform incorporates advances across three components, mRNA, delivery, and the manufacturing process, to advance its medicines. Its products are Spikevax and mNEXSPIKE (its COVID vaccines), and mRESVIA (its vaccine against respiratory syncytial virus (RSV)). It also has a diverse development pipeline that consists of 35 therapeutic and vaccine programs, six of which are in late-stage development. It has regulatory filings under review for its seasonal flu+COVID vaccine (mRNA-1083) in Europe and Canada and for its seasonal flu vaccine (mRNA-1010) in the United States, Europe, Canada and Australia. Its rare disease programs are Propionic acidemia (mRNA-3927); Methylmalonic acidemia (mRNA-3705), and Cystic Fibrosis (mRNA-3692/VX-522).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Moderna Initiates Hantavirus Vaccine Development
- Vaccine Development Progress: Moderna is collaborating with the U.S. Army Medical Research Institute of Infectious Diseases to develop a hantavirus vaccine in early stages, although availability may take years, reflecting the company's commitment to addressing emerging infectious diseases.
- Positive Market Reaction: Moderna's shares rose approximately 14% in Friday afternoon trading, indicating investor optimism regarding the new vaccine development, which could enhance its market competitiveness.
- Epidemic Context Impact: Hantavirus has gained renewed attention due to an outbreak on the MV Hondius cruise ship, which resulted in three deaths and at least six infections, highlighting the urgency for vaccine development as noted by the World Health Organization.
- Funding Challenges and Outlook: Despite the challenges of insufficient funding for hantavirus vaccine development, experts suggest that without significant government investment, the timeline for vaccine availability could extend to a decade or more, impacting the company's long-term strategic planning.
See More
Healthcare Stocks Rise in Premarket Trading
- Healthcare Stock Surge: Healthcare stocks are rising in premarket trading on Monday, indicating a positive sentiment in the market, likely influenced by investor optimism regarding potential healthcare policy changes.
- Positive Market Reaction: The increased attention on the healthcare sector may stem from recent discussions around health-related policies, which are expected to drive growth in healthcare spending and enhance profitability for related companies.
- Selective Investment in Sector: As healthcare stocks rise, investors may reassess their portfolios, increasing allocations to the healthcare sector to seek better risk-adjusted returns amid future market volatility.
- Policy Impact Potential: Potential changes in healthcare policy could present new growth opportunities for healthcare stocks, particularly in the fields of innovative drugs and medical technologies, further boosting market confidence in the sector.
See More
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Innovative Therapies to Overcome Blood-Brain Barrier Challenges
- Blood-Brain Barrier Challenge: Research indicates that approximately 98% of small-molecule drugs and nearly all biologics fail to penetrate the blood-brain barrier effectively, leading to a high failure rate in CNS drug development, highlighting the urgent need for innovative delivery methods to address this bottleneck.
- Oncotelic's N2B System: Oncotelic Therapeutics has launched its proprietary intranasal nose-to-brain (N2B) delivery system, which enables rapid drug delivery to the brain, aiming to tackle drug delivery issues in Alzheimer's disease and biodefense, showcasing its strategic significance in the biopharma industry.
- Rising Alzheimer’s Burden: Over 57 million people globally are currently facing dementia, a number expected to rise significantly in the coming decades, placing immense strain on healthcare systems and economies, with Oncotelic's technology potentially improving this situation.
- Biodefense Demand: As biological and chemical threats increase, government agencies are prioritizing the need for rapid and effective CNS drug delivery, and Oncotelic's technology can provide quick interventions in emergencies, reflecting its importance in national security.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Innovative Therapies Overcoming Blood-Brain Barrier Challenges
- Blood-Brain Barrier Challenge: The blood-brain barrier restricts approximately 98% of small-molecule drugs and nearly all biologics from effective penetration, leading to a high failure rate in CNS drug development, highlighting the urgent need for innovative delivery methods to improve therapeutic outcomes.
- Oncotelic's N2B System: Oncotelic Therapeutics has launched its proprietary intranasal nose-to-brain (N2B) system aimed at rapidly and effectively delivering drugs to the central nervous system, having established a strategic partnership with Lunai Bioworks focusing on biodefense and Alzheimer's disease treatment.
- Global Alzheimer's Burden: Over 57 million people worldwide are currently living with dementia, a number expected to rise significantly in the coming decades, placing immense strain on healthcare systems and economies, underscoring the necessity for effective drug delivery systems.
- Urgency in Biodefense: In biodefense, rapid and effective drug delivery is crucial, with government agencies increasingly prioritizing medical countermeasures capable of addressing chemical and biological threats, positioning Oncotelic's technology as a vital solution.
See More
Moderna Initiates Hantavirus Vaccine Development
- Vaccine Development Progress: Moderna is collaborating with the U.S. Army Medical Research Institute of Infectious Diseases to develop a hantavirus vaccine in early stages, although availability may take years, reflecting the company's commitment to addressing emerging infectious diseases.
- Positive Market Reaction: Moderna's shares rose approximately 14% in Friday afternoon trading, indicating investor optimism regarding the new vaccine development, which could enhance its market competitiveness.
- Epidemic Context Impact: Hantavirus has gained renewed attention due to an outbreak on the MV Hondius cruise ship, which resulted in three deaths and at least six infections, highlighting the urgency for vaccine development as noted by the World Health Organization.
- Funding Challenges and Outlook: Despite the challenges of insufficient funding for hantavirus vaccine development, experts suggest that without significant government investment, the timeline for vaccine availability could extend to a decade or more, impacting the company's long-term strategic planning.
See More
Healthcare Stocks Rise in Premarket Trading
- Healthcare Stock Surge: Healthcare stocks are rising in premarket trading on Monday, indicating a positive sentiment in the market, likely influenced by investor optimism regarding potential healthcare policy changes.
- Positive Market Reaction: The increased attention on the healthcare sector may stem from recent discussions around health-related policies, which are expected to drive growth in healthcare spending and enhance profitability for related companies.
- Selective Investment in Sector: As healthcare stocks rise, investors may reassess their portfolios, increasing allocations to the healthcare sector to seek better risk-adjusted returns amid future market volatility.
- Policy Impact Potential: Potential changes in healthcare policy could present new growth opportunities for healthcare stocks, particularly in the fields of innovative drugs and medical technologies, further boosting market confidence in the sector.
See More
Hantavirus Outbreak Triggers Surge in Pharma Stocks
- Pharma Stock Surge: Following the WHO's May 2 warning about the hantavirus outbreak, Moderna's stock rose 7% in premarket trading, indicating market confidence in its ability to address emerging infectious diseases.
- Research Collaboration: Moderna is conducting preclinical research on hantaviruses in collaboration with the US Army Medical Research Institute, although Evercore ISI believes this will not lead to significant revenue opportunities, it highlights the agility of its mRNA platform.
- Other Companies' Performance: Inovio Pharmaceuticals jumped 11% in early trading, while Novavax rose 5%, reflecting positive market sentiment towards vaccine development firms, despite limited overall market opportunities.
- Epidemic Control Status: President Trump stated that the outbreak on the cruise ship is under control, with the WHO reporting 8 confirmed cases and 3 deaths, assessing the public health risk as low, indicating the situation is manageable.
See More
Innovative Therapies to Overcome Blood-Brain Barrier Challenges
- Blood-Brain Barrier Challenge: Research indicates that approximately 98% of small-molecule drugs and nearly all biologics fail to penetrate the blood-brain barrier effectively, leading to a high failure rate in CNS drug development, highlighting the urgent need for innovative delivery methods to address this bottleneck.
- Oncotelic's N2B System: Oncotelic Therapeutics has launched its proprietary intranasal nose-to-brain (N2B) delivery system, which enables rapid drug delivery to the brain, aiming to tackle drug delivery issues in Alzheimer's disease and biodefense, showcasing its strategic significance in the biopharma industry.
- Rising Alzheimer’s Burden: Over 57 million people globally are currently facing dementia, a number expected to rise significantly in the coming decades, placing immense strain on healthcare systems and economies, with Oncotelic's technology potentially improving this situation.
- Biodefense Demand: As biological and chemical threats increase, government agencies are prioritizing the need for rapid and effective CNS drug delivery, and Oncotelic's technology can provide quick interventions in emergencies, reflecting its importance in national security.
See More
Hantavirus Outbreak Drives Pharmaceutical Stocks Up
- Pharmaceutical Stocks Surge: Following the hantavirus outbreak, pharmaceutical stocks such as Moderna, Inovio, Novavax, and Emergent Biosolutions saw significant premarket gains, with Moderna rising 7%, Inovio up 13%, and Emergent and Novavax increasing by 4% and 3% respectively, indicating heightened investor interest in outbreak-related companies.
- Market Reaction Analysis: Evercore ISI analysts noted that despite the stock increases, the revenue opportunity from hantavirus is limited, suggesting that the current price fluctuations are primarily sentiment-driven rather than based on fundamental changes, and highlighting that Moderna's mRNA platform agility is already well understood by the market.
- Epidemic Background: The World Health Organization confirmed the hantavirus outbreak on May 2, stating that the virus is transmitted by rodents; although there have been 8 reported cases and 3 deaths, the public health risk is assessed as low, indicating that the severity of the outbreak is limited.
- Government Response Measures: U.S. President Trump stated that the outbreak is under control and promised a report on the virus soon, emphasizing the government's proactive stance in managing the situation, which may further influence market sentiment and investor confidence.
See More
Innovative Therapies Overcoming Blood-Brain Barrier Challenges
- Blood-Brain Barrier Challenge: The blood-brain barrier restricts approximately 98% of small-molecule drugs and nearly all biologics from effective penetration, leading to a high failure rate in CNS drug development, highlighting the urgent need for innovative delivery methods to improve therapeutic outcomes.
- Oncotelic's N2B System: Oncotelic Therapeutics has launched its proprietary intranasal nose-to-brain (N2B) system aimed at rapidly and effectively delivering drugs to the central nervous system, having established a strategic partnership with Lunai Bioworks focusing on biodefense and Alzheimer's disease treatment.
- Global Alzheimer's Burden: Over 57 million people worldwide are currently living with dementia, a number expected to rise significantly in the coming decades, placing immense strain on healthcare systems and economies, underscoring the necessity for effective drug delivery systems.
- Urgency in Biodefense: In biodefense, rapid and effective drug delivery is crucial, with government agencies increasingly prioritizing medical countermeasures capable of addressing chemical and biological threats, positioning Oncotelic's technology as a vital solution.
See More
